NMS-173 / Nerviano Medical Sciences - LARVOL DELTA

Nerviano Medical Sciences announces strategic portfolio shaping. (NMS Group) - "Nerviano Medical Sciences S.r.l...announces the strategic discontinuation of three development programs to further prioritize and reinforce efforts on core programs. NMS-088...The decision is the result of internal analysis of the benefit profile of the drug in the third line (3L) setting in patients who are refractory or relapsed after standard of care including prior FLT3 inhibitors and considering the further development in rapidly changing AML treatments. NMS will report the data in in the first half of 2025...NMS-173, a potent covalent orally available, second-generation dual IDH1/ IDH2 inhibitor...NMS-341, a late preclinical-stage next-generation inhibitor of CDC7..."

Clinical data • Discontinued • Acute Myelogenous Leukemia • Biliary Tract Cancer • Cholangiocarcinoma • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor (AACR-NCI-EORTC 2022) - "NMS-173 induced stronger and more durable efficacy than ivosidenib in the HCCC-9810 IDH1 mutant cholangiocarcinoma xenograft model and increased the survival of mice bearing the LEXFAM2734 IDH1 mutant PDX AML line, with a better disease control compared to ivosidenib. NMS-173 is a second generation, dual IDH1/ IDH2 inhibitor with a covalent mode of action, inducing abrogation of 2-HG production and anti-tumor efficacy in IDH mutant mouse models superior to competitors. NMS-173 has the potential for better efficacy compared to FDA approved drugs and has received authorization to start phase I clinical studies. No"

Acute Myelogenous Leukemia • Biliary Cancer • Brain Cancer • Cholangiocarcinoma • CNS Tumor • Fibrosarcoma • Gastrointestinal Cancer • Glioma • Hematological Malignancies • Oncology • Sarcoma • Solid Tumor • IDH1